CP-690,550 Pharmacokinetics In Healthy Chinese Subjects

Pfizer

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: CP-690,550

Study type: Interventional

Funder types: Industry

Identifiers

NCT01101919

A3921065

Details and patient eligibility

About

This study is designed to evaluate the levels of CP-690,550 in the blood of healthy Chinese subjects following both single doses and multiple doses of drug.

Enrollment: 12 estimated patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Chinese Volunteers
• No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Exclusion criteria

• Clinically significant infections within the past 3 months
• Positive screening test for hepatitis B surface antigen, anti-hepatitis C antibody, or human immunodeficiency virus
• Pregnant or nursing women

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

CP-690,550 Dose Group

Experimental group

Treatment:

Drug: CP-690,550